Literature DB >> 7539042

Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites.

G Karupiah1, N Harris.   

Abstract

IFN-gamma-induced nitric oxide (NO) in the murine macrophage-derived cell line RAW 264.7 was previously shown to inhibit replication of the poxviruses ectromelia and vaccinia (VV) and HSV-1. In the current study we demonstrate that murine macrophages activated as a consequence of VV infection express inducible nitric oxide synthase. These activated macrophages were resistant to infection with VV and efficiently blocked the replication of VV and HSV-1 in infected bystander cells of epithelial and fibroblast origin. This inhibition was arginine dependent, correlated with nitrite production in cultures, and reversible by the NOS inhibitor N omega-monomethyl-L-arginine. NO-mediated inhibition of VV replication was studied by treatment of virus-infected human 293 cells with the NO donor S-nitroso-N-acetyl-penicillamine. Using a VV-specific DNA probe, antibodies specific for temporally expressed viral proteins, and transmission electron microscopy, we have shown that NO inhibited viral late gene protein synthesis, DNA replication, and virus particle formation, but not expression of the early proteins that were analyzed. Putative enzymatic targets of NO were identified by reversing the NO-mediated inhibition of VV replication in the 293 cells with exogenous ferrous sulfate and L-cysteine. Reversal of inhibition may derive from the capacity of these reagents to protect or regenerate nonheme iron or thiol groups, respectively, which are essential for the catalytic activities of enzymes susceptible to inactivation by NO.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539042      PMCID: PMC2192048          DOI: 10.1084/jem.181.6.2171

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  Cloning and characterization of inducible nitric oxide synthase from mouse macrophages.

Authors:  Q W Xie; H J Cho; J Calaycay; R A Mumford; K M Swiderek; T D Lee; A Ding; T Troso; C Nathan
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor?

Authors:  G Karupiah; R V Blanden
Journal:  Immunol Cell Biol       Date:  1990-10       Impact factor: 5.126

Review 3.  Role of nitric oxide synthesis in macrophage antimicrobial activity.

Authors:  C F Nathan; J B Hibbs
Journal:  Curr Opin Immunol       Date:  1991-02       Impact factor: 7.486

4.  Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein.

Authors:  D J Stuehr; H J Cho; N S Kwon; M F Weise; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 5.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

6.  L-arginine transport is increased in macrophages generating nitric oxide.

Authors:  R G Bogle; A R Baydoun; J D Pearson; S Moncada; G E Mann
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

7.  Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages.

Authors:  D L Granger; J B Hibbs; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages.

Authors:  J R Lancaster; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

9.  Inactivation of ribonucleotide reductase by nitric oxide.

Authors:  M Lepoivre; F Fieschi; J Coves; L Thelander; M Fontecave
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

10.  Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.

Authors:  N S Kwon; D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  31 in total

1.  Nitric oxide inhibition of coxsackievirus replication in vitro.

Authors:  C Zaragoza; C J Ocampo; M Saura; A McMillan; C J Lowenstein
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 2.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.

Authors:  A F Vanin; A V Pekshev; A B Vagapov; N A Sharapov; V L Lakomkin; A A Abramov; A A Timoshin; V I Kapelko
Journal:  Biophysics (Oxf)       Date:  2021-04-27

Review 4.  Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity.

Authors:  F C Fang
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

5.  Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication.

Authors:  Y L Lin; Y L Huang; S H Ma; C T Yeh; S Y Chiou; L K Chen; C L Liao
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Nitric oxide inhibits HIV tat-induced NF-kappaB activation.

Authors:  F Chen; Y Lu; V Castranova; Y Rojanasakul; K Miyahara; Y Shizuta; V Vallyathan; X Shi; L M Demers
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

7.  A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo.

Authors:  M S Rolph; W B Cowden; C J Medveczky; I A Ramshaw
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Activity of nitric oxide-generating compounds against encephalomyocarditis virus.

Authors:  E Guillemard; M Geniteau-Legendre; R Kergot; G Lemaire; J F Petit; C Labarre; A M Quero
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 9.  Iron withholding: a defense against viral infections.

Authors:  E D Weinberg
Journal:  Biometals       Date:  1996-10       Impact factor: 2.949

10.  Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.

Authors:  Patrick C Reading; Geoffrey L Smith
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.